Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 113

1.

Are genetic and idiopathic forms of Parkinson's disease the same disease?

Correia Guedes L, Mestre T, Outeiro TF, Ferreira JJ.

J Neurochem. 2019 Oct 23. doi: 10.1111/jnc.14902. [Epub ahead of print] Review.

PMID:
31643079
2.

Intermittent undulating tongue as an involuntary movement in early amyotrophic lateral sclerosis.

Breiner A, Basndwah A, Warman-Chardon J, Bourque PR, Mestre TA.

Parkinsonism Relat Disord. 2019 Sep 3;67:1-2. doi: 10.1016/j.parkreldis.2019.09.002. [Epub ahead of print] No abstract available.

PMID:
31621597
3.

Canadian guideline for Parkinson disease.

Grimes D, Fitzpatrick M, Gordon J, Miyasaki J, Fon EA, Schlossmacher M, Suchowersky O, Rajput A, Lafontaine AL, Mestre T, Appel-Cresswell S, Kalia SK, Schoffer K, Zurowski M, Postuma RB, Udow S, Fox S, Barbeau P, Hutton B.

CMAJ. 2019 Sep 9;191(36):E989-E1004. doi: 10.1503/cmaj.181504. No abstract available.

4.

Synuclein Meeting 2019: where we are and where we need to go.

Outeiro TF, Mestre TA.

J Neurochem. 2019 Sep;150(5):462-466. doi: 10.1111/jnc.14825.

PMID:
31441047
5.

The dawn of a new era for neurodegenerative disorders: Huntington's disease leading the way.

Mestre TA, Guttman M.

Mov Disord. 2019 Sep;34(9):1301-1302. doi: 10.1002/mds.27826. Epub 2019 Aug 21. No abstract available.

PMID:
31433876
6.

An 8-year-old boy with ataxia and abnormal movements.

Hanes I, Mestre T, Doja A.

Paediatr Child Health. 2019 Aug;24(5):297-298. doi: 10.1093/pch/pxy178. Epub 2018 Dec 26. No abstract available.

PMID:
31379427
7.

Nocebo response in Parkinson's disease: A systematic review and meta-analysis.

Leal Rato M, Duarte GS, Ferreira AN, Alves M, Mainoli B, Teodoro T, Mestre TA, Costa J, Ferreira JJ.

Parkinsonism Relat Disord. 2019 Aug;65:13-19. doi: 10.1016/j.parkreldis.2019.04.015. Epub 2019 Apr 20. Review.

PMID:
31103487
8.

MDS evidence-based review of treatments for essential tremor.

Ferreira JJ, Mestre TA, Lyons KE, Benito-León J, Tan EK, Abbruzzese G, Hallett M, Haubenberger D, Elble R, Deuschl G; MDS Task Force on Tremor and the MDS Evidence Based Medicine Committee.

Mov Disord. 2019 Jul;34(7):950-958. doi: 10.1002/mds.27700. Epub 2019 May 2. Review.

PMID:
31046186
9.

Amelioration of the Oxidative Stress Generated by Simple or Combined Abiotic Stress through the K⁺ and Ca2+ Supplementation in Tomato Plants.

García-Martí M, Piñero MC, García-Sanchez F, Mestre TC, López-Delacalle M, Martínez V, Rivero RM.

Antioxidants (Basel). 2019 Mar 30;8(4). pii: E81. doi: 10.3390/antiox8040081.

10.

A roadmap for implementation of patient-centered digital outcome measures in Parkinson's disease obtained using mobile health technologies.

Espay AJ, Hausdorff JM, Sánchez-Ferro Á, Klucken J, Merola A, Bonato P, Paul SS, Horak FB, Vizcarra JA, Mestre TA, Reilmann R, Nieuwboer A, Dorsey ER, Rochester L, Bloem BR, Maetzler W; Movement Disorder Society Task Force on Technology.

Mov Disord. 2019 May;34(5):657-663. doi: 10.1002/mds.27671. Epub 2019 Mar 22. Review.

PMID:
30901495
11.

The Parkinson's disease e-diary: Developing a clinical and research tool for the digital age.

Vizcarra JA, Sánchez-Ferro Á, Maetzler W, Marsili L, Zavala L, Lang AE, Martinez-Martin P, Mestre TA, Reilmann R, Hausdorff JM, Dorsey ER, Paul SS, Dexheimer JW, Wissel BD, Fuller RLM, Bonato P, Tan AH, Bloem BR, Kopil C, Daeschler M, Bataille L, Kleiner G, Cedarbaum JM, Klucken J, Merola A, Goetz CG, Stebbins GT, Espay AJ; MDS Technology Task Force and the MDS Rating Scales Program Electronic Development Ad-Hoc Committee.

Mov Disord. 2019 May;34(5):676-681. doi: 10.1002/mds.27673. Epub 2019 Mar 22. No abstract available.

PMID:
30901492
12.

Reply to "Studying reproducibility of data-driven Parkinson's disease subtypes".

Mestre TA, Eberly S, Tanner C, Grimes D, Lang AE, Oakes D, Marras C.

Parkinsonism Relat Disord. 2019 Sep;66:245-246. doi: 10.1016/j.parkreldis.2018.12.028. Epub 2018 Dec 28. No abstract available.

PMID:
30655161
13.

Recent advances in the therapeutic development for Huntington disease.

Mestre TA.

Parkinsonism Relat Disord. 2019 Feb;59:125-130. doi: 10.1016/j.parkreldis.2018.12.003. Epub 2018 Dec 12.

PMID:
30616867
14.

Development of the Integrated Parkinson's Care Network (IPCN): using co-design to plan collaborative care for people with Parkinson's disease.

Kessler D, Hauteclocque J, Grimes D, Mestre T, Côtéd D, Liddy C.

Qual Life Res. 2019 May;28(5):1355-1364. doi: 10.1007/s11136-018-2092-0. Epub 2019 Jan 2.

PMID:
30600492
15.

Vision-based assessment of parkinsonism and levodopa-induced dyskinesia with pose estimation.

Li MH, Mestre TA, Fox SH, Taati B.

J Neuroeng Rehabil. 2018 Nov 6;15(1):97. doi: 10.1186/s12984-018-0446-z.

16.

Introducing the new "Movement Disorders Rounds".

Mestre TA, Bhidayasiri R.

Parkinsonism Relat Disord. 2018 Oct;55:1. doi: 10.1016/j.parkreldis.2018.09.024. No abstract available.

PMID:
30396637
17.

Rating Scales and Performance-based Measures for Assessment of Functional Ability in Huntington's Disease: Critique and Recommendations.

Mestre TA, Busse M, Davis AM, Quinn L, Rodrigues FB, Burgunder JM, Carlozzi NE, Walker F, Ho AK, Sampaio C, Goetz CG, Cubo E, Martinez-Martin P, Stebbins GT; Members of the MDS Committee on Rating Scales Development.

Mov Disord Clin Pract. 2018 May 9;5(4):361-372. doi: 10.1002/mdc3.12617. eCollection 2018 Jul-Aug.

18.

Rating Scales for Motor Symptoms and Signs in Huntington's Disease: Critique and Recommendations.

Mestre TA, Forjaz MJ, Mahlknecht P, Cardoso F, Ferreira JJ, Reilmann R, Sampaio C, Goetz CG, Cubo E, Martinez-Martin P, Stebbins GT; Members of the Movement Disorder Society Committee on Rating Scales Development.

Mov Disord Clin Pract. 2018 Jan 3;5(2):111-117. doi: 10.1002/mdc3.12571. eCollection 2018 Mar-Apr.

19.

Strong nocebo effect in amyotrophic lateral sclerosis trials might mask conclusions.

Rato ML, Duarte GS, Mestre T, de Carvalho M, Ferreira JJ.

Lancet Neurol. 2018 Oct;17(10):842. doi: 10.1016/S1474-4422(18)30310-7. Epub 2018 Sep 18. No abstract available.

PMID:
30264722
20.

Investigating Voice as a Biomarker for Leucine-Rich Repeat Kinase 2-Associated Parkinson's Disease.

Arora S, Visanji NP, Mestre TA, Tsanas A, AlDakheel A, Connolly BS, Gasca-Salas C, Kern DS, Jain J, Slow EJ, Faust-Socher A, Lang AE, Little MA, Marras C.

J Parkinsons Dis. 2018;8(4):503-510. doi: 10.3233/JPD-181389.

21.

The placebo response in Parkinson's disease and other movement disorders.

Mestre TA, Ferreira JJ.

Mov Disord. 2018 Aug;33(8):1193-1194. doi: 10.1002/mds.27476. No abstract available.

PMID:
30230628
22.

Placebo and nocebo responses in other movement disorders besides Parkinson's disease: How much do we know?

Ferreira JJ, Trenkwalder C, Mestre TA.

Mov Disord. 2018 Aug;33(8):1228-1235. doi: 10.1002/mds.113. Review.

PMID:
30230626
23.

Assessing and managing Parkinson's disease from home: A 21st century vision closer to reality.

Mestre TA.

Mov Disord. 2018 Sep;33(9):1407. doi: 10.1002/mds.112. Epub 2018 Sep 14. No abstract available.

PMID:
30216537
24.

Harnessing the power of placebos in movement disorders: Insights from Parkinson's disease in clinical research and practice.

Mestre TA, Shamy M, Benedetti F, Lang AE.

Mov Disord. 2018 Aug;33(8):1195-1203. doi: 10.1002/mds.27409. Epub 2018 Aug 25. Review.

PMID:
30145820
25.

Reproducibility of data-driven Parkinson's disease subtypes for clinical research.

Mestre TA, Eberly S, Tanner C, Grimes D, Lang AE, Oakes D, Marras C.

Parkinsonism Relat Disord. 2018 Nov;56:102-106. doi: 10.1016/j.parkreldis.2018.07.009. Epub 2018 Jul 20. Review.

PMID:
30056038
26.

Squamous Cell Carcinoma and Multiple Familial Trichoepitheliomas: A Recurrent Association.

Dubois A, Mestre T, Oliphant T, Husain A, Rajan N.

Acta Derm Venereol. 2018 Oct 10;98(9):910-911. doi: 10.2340/00015555-2988. No abstract available.

27.

Automated assessment of levodopa-induced dyskinesia: Evaluating the responsiveness of video-based features.

Li MH, Mestre TA, Fox SH, Taati B.

Parkinsonism Relat Disord. 2018 Aug;53:42-45. doi: 10.1016/j.parkreldis.2018.04.036. Epub 2018 May 5.

PMID:
29748112
28.

Clustering of motor and nonmotor traits in leucine-rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study.

Mestre TA, Pont-Sunyer C, Kausar F, Visanji NP, Ghate T, Connolly BS, Gasca-Salas C, Kern DS, Jain J, Slow EJ, Faust-Socher A, Kasten M, Wadia PM, Zadikoff C, Kumar P, de Bie RM, Thomsen T, Lang AE, Schüle B, Klein C, Tolosa E, Marras C.

Mov Disord. 2018 Jul;33(6):960-965. doi: 10.1002/mds.27272. Epub 2018 Apr 17.

PMID:
29665080
29.

Quality of Life in Huntington's Disease: Critique and Recommendations for Measures Assessing Patient Health-Related Quality of Life and Caregiver Quality of Life.

Mestre TA, Carlozzi NE, Ho AK, Burgunder JM, Walker F, Davis AM, Busse M, Quinn L, Rodrigues FB, Sampaio C, Goetz CG, Cubo E, Martinez-Martin P, Stebbins GT; Members of the MDS Committee on Rating Scales Development.

Mov Disord. 2018 May;33(5):742-749. doi: 10.1002/mds.27317. Epub 2018 Mar 23. Review.

30.

Tolerance to Stress Combination in Tomato Plants: New Insights in the Protective Role of Melatonin.

Martinez V, Nieves-Cordones M, Lopez-Delacalle M, Rodenas R, Mestre TC, Garcia-Sanchez F, Rubio F, Nortes PA, Mittler R, Rivero RM.

Molecules. 2018 Feb 28;23(3). pii: E535. doi: 10.3390/molecules23030535.

31.

Actigraphy Detects Greater Intra-Individual Variability During Gait in Non-Manifesting LRRK2 Mutation Carriers.

van den Heuvel L, Lim AS, Visanji NP, Huang J, Ghate T, Mestre TA, AlDakheel A, Connolly BS, Gasca-Salas C, Kern DS, Jain J, Slow EJ, Pondal M, Faust-Socher A, Rogaeva E, Tomlinson G, Lang AE, Marras C.

J Parkinsons Dis. 2018;8(1):131-139. doi: 10.3233/JPD-171151.

PMID:
29480219
32.

A rare cause of orofacial dyskinesias.

Miranda B, Mestre TA, Rodrigues D, Coelho M, Ferreira JJ.

Parkinsonism Relat Disord. 2018 May;50:122-123. doi: 10.1016/j.parkreldis.2018.02.002. Epub 2018 Feb 7. No abstract available.

PMID:
29429646
33.

Correction: Gene Expression Differences in Peripheral Blood of Parkinson's Disease Patients with Distinct Progression Profiles.

Pinho R, Guedes LC, Soreq L, Lobo PP, Mestre T, Coelho M, Rosa MM, Gonçalves N, Wales P, Mendes T, Gerhardt E, Fahlbusch C, Bonifati V, Bonin M, Miltenberger-Miltényi G, Borovecki F, Soreq H, Ferreira JJ, Outeiro TF.

PLoS One. 2017 Dec 28;12(12):e0190552. doi: 10.1371/journal.pone.0190552. eCollection 2017.

34.

Rating scales for cognition in Huntington's disease: Critique and recommendations.

Mestre TA, Bachoud-Lévi AC, Marinus J, Stout JC, Paulsen JS, Como P, Duff K, Sampaio C, Goetz CG, Cubo E, Stebbins GT, Martinez-Martin P; Members of the MDS Committee on Rating Scales Development.

Mov Disord. 2018 Feb;33(2):187-195. doi: 10.1002/mds.27227. Epub 2017 Dec 26. Review.

PMID:
29278291
35.

Huntington disease care: From the past to the present, to the future.

Mestre TA, Shannon K.

Parkinsonism Relat Disord. 2017 Nov;44:114-118. doi: 10.1016/j.parkreldis.2017.08.009. Epub 2017 Aug 10. Review.

PMID:
29089255
36.

Automated vision-based analysis of levodopa-induced dyskinesia with deep learning.

Li MH, Mestre TA, Fox SH, Taati B.

Conf Proc IEEE Eng Med Biol Soc. 2017 Jul;2017:3377-3380. doi: 10.1109/EMBC.2017.8037580.

PMID:
29060621
37.

Fifteen Years of Clinical Trials in Huntington's Disease: A Very Low Clinical Drug Development Success Rate.

Travessa AM, Rodrigues FB, Mestre TA, Ferreira JJ.

J Huntingtons Dis. 2017;6(2):157-163. doi: 10.3233/JHD-170245.

PMID:
28671135
38.

Placebo and nocebo responses in restless legs syndrome: A systematic review and meta-analysis.

Silva MA, Duarte GS, Camara R, Rodrigues FB, Fernandes RM, Abreu D, Mestre T, Costa J, Trenkwalder C, Ferreira JJ.

Neurology. 2017 Jun 6;88(23):2216-2224. doi: 10.1212/WNL.0000000000004004. Epub 2017 May 10. Review.

PMID:
28490647
39.

Huntington Disease: Linking Pathogenesis to the Development of Experimental Therapeutics.

Mestre TA, Sampaio C.

Curr Neurol Neurosci Rep. 2017 Feb;17(2):18. doi: 10.1007/s11910-017-0711-8. Review.

PMID:
28265888
40.

Blue intensity matters for cell cycle profiling in fluorescence DAPI-stained images.

Ferro A, Mestre T, Carneiro P, Sahumbaiev I, Seruca R, Sanches JM.

Lab Invest. 2017 May;97(5):615-625. doi: 10.1038/labinvest.2017.13. Epub 2017 Mar 6.

41.

Response to letter by Saenz-Farret et al. on "Rating scales for behavioral symptoms in Huntington's disease: Critique and recommendations".

Mestre TA, van Duijn E, Davis AM, Bachoud-Lévi AC, Busse M, Anderson KE, Sampaio C, Goetz CG, Cubo E, Stebbins GT, Martinez-Martin P; Members of the MDS Committee on Rating Scales Development.

Mov Disord. 2017 Mar;32(3):482. doi: 10.1002/mds.26954. Epub 2017 Mar 3. No abstract available.

PMID:
28256103
42.

Impact of New Technologies in a Stroke Presentation: A Case of Dystextia and Dystypia.

Thomas NWD, Mestre TA.

Can J Neurol Sci. 2017 Jul;44(4):458-460. doi: 10.1017/cjn.2016.431. Epub 2017 Feb 13. No abstract available.

PMID:
28190405
43.

Are placebo pills presented as experimental treatment a true placebo?

Mestre TA, Ferreira JJ.

Pain. 2017 Mar;158(3):535. doi: 10.1097/j.pain.0000000000000793. No abstract available.

PMID:
28187103
44.

Heart rate variability in leucine-rich repeat kinase 2-associated Parkinson's disease.

Visanji NP, Bhudhikanok GS, Mestre TA, Ghate T, Udupa K, AlDakheel A, Connolly BS, Gasca-Salas C, Kern DS, Jain J, Slow EJ, Faust-Socher A, Kim S, Azhu Valappil R, Kausar F, Rogaeva E, William Langston J, Tanner CM, Schüle B, Lang AE, Goldman SM, Marras C.

Mov Disord. 2017 Apr;32(4):610-614. doi: 10.1002/mds.26896. Epub 2017 Jan 10.

PMID:
28071824
45.

Placebos in clinical trials: unravelling a complex phenomenon.

Mestre TA, Lang AE.

Lancet Neurol. 2017 Jan;16(1):28-29. doi: 10.1016/S1474-4422(16)30349-0. No abstract available.

PMID:
27979350
46.

Modelling idiopathic Parkinson disease as a complex illness can inform incidence rate in healthy adults: the PR EDIGT score.

Schlossmacher MG, Tomlinson JJ, Santos G, Shutinoski B, Brown EG, Manuel D, Mestre T.

Eur J Neurosci. 2017 Jan;45(1):175-191. doi: 10.1111/ejn.13476. Epub 2016 Dec 27.

47.

Atomic force microscopy and graph analysis to study the P-cadherin/SFK mechanotransduction signalling in breast cancer cells.

Ribeiro AS, Carvalho FA, Figueiredo J, Carvalho R, Mestre T, Monteiro J, Guedes AF, Fonseca M, Sanches J, Seruca R, Santos NC, Paredes J.

Nanoscale. 2016 Nov 24;8(46):19390-19401.

PMID:
27847941
48.

Chorea.

Mestre TA.

Continuum (Minneap Minn). 2016 Aug;22(4 Movement Disorders):1186-207. doi: 10.1212/CON.0000000000000349. Review.

PMID:
27495204
49.

Corrigendum: Quantification of topological features in cell meshes to explore E-cadherin dysfunction.

Mestre T, Figueiredo J, Ribeiro AS, Paredes J, Seruca R, Sanches JM.

Sci Rep. 2016 Jul 27;6:30222. doi: 10.1038/srep30222. No abstract available.

50.

Long-term double-blinded unilateral pedunculopontine area stimulation in Parkinson's disease.

Mestre TA, Sidiropoulos C, Hamani C, Poon YY, Lozano AM, Lang AE, Moro E.

Mov Disord. 2016 Oct;31(10):1570-1574. doi: 10.1002/mds.26710.

PMID:
27392513

Supplemental Content

Loading ...
Support Center